Compare Fox Corp Class B (FOX) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Twist Bioscience Corp — how do they compare? Fox Corp Class B trades at $51.01 (market cap $22.28B), while Twist Bioscience Corp trades at $90.4 (market cap $5.76B). The key difference: Fox Corp Class B is far larger — about 3.9× Twist Bioscience Corp's market cap, and Fox Corp Class B pays a 1.11% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| FOX | TWST | |
|---|---|---|
Market Cap | $22.28B | $5.76B |
Sector | Media | Health |
52-Week High | $67.76 | $102.88 |
52-Week Low | $44.39 | $24.16 |
Enterprise Value | $26.25B | $5.69B |
Dividend Yield | 1.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Fox Corporation (FOX) trades at $51.06, up 3.15% with strong recent earnings beats. The stock shows mixed technical signals with bearish moving averages but neutral oscillators. Fundamentally, the company delivered robust 2025 results with $16.3B revenue and $2.26B net income, supported by improved cash flow generation. Recent news highlights Fox's strategic positioning in streaming and advertising growth.
Fox presents a compelling value opportunity with reasonable valuation multiples (P/E 13.26, P/S 1.39) and consistent earnings outperformance. However, technical weakness and competitive pressures in media streaming require monitoring. Analyst consensus leans positive with 42.86% buy ratings, though execution risks in the Roku integration and advertising market volatility remain key considerations.
Twist Bioscience (TWST) trades at $90.33, down 2.46% on the day, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst sentiment is positive with 11 buy ratings and a $91.63 consensus target, while recent news highlights AI collaborations and upcoming Q3 earnings.
TWST presents a growth story with improving margins and AI-driven demand, but profitability concerns and consistent cash burn pose risks. The stock trades near analyst targets, suggesting limited near-term upside without earnings acceleration. Key catalysts include Q3 results on August 3, 2026, and execution on path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
